BioSpace News Archive

Rhythm Pharmaceuticals, Inc. announced that on September 2, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 84,800 shares of its common stock to 15 new employees, consisting of inducement stock options to purchase an aggregate of 56,520 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 28,280 shares of its common stock.

Exaktera LLC, (“Exaktera”), a Union Park Capital (“Union Park”) portfolio company, is pleased to announce its acquisition of Advanced Illumination Inc. (“Advanced Illumination”), a long-established design and manufacturer of specialty LED lighting assemblies and drivers for machine vision, industrial imaging, bio-medical and related imaging applications.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced it has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.

Oyster Point Pharma, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 242,600 shares of common stock to 36 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies

EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022.

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC).

BeiGene announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET.

Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France.

Vanda Pharmaceuticals Inc. announced the notice of opportunity for an FDA hearing on Vanda’s Supplemental New Drug Application for HETLIOZ® to treat jet lag disorder.